OraSure - 500 Beiträge pro Seite
eröffnet am 30.03.04 11:52:30 von
neuester Beitrag 30.03.04 12:32:06 von
neuester Beitrag 30.03.04 12:32:06 von
Beiträge: 2
ID: 841.706
ID: 841.706
Aufrufe heute: 0
Gesamt: 767
Gesamt: 767
Aktive User: 0
ISIN: US68554V1089 · WKN: 881351 · Symbol: EP3
6,3000
EUR
+2,44 %
+0,1500 EUR
Letzter Kurs 18.03.24 Tradegate
Neuigkeiten
20.07.23 · globenewswire |
20.07.23 · globenewswire |
13.06.23 · globenewswire |
10.05.23 · globenewswire |
03.05.23 · globenewswire |
Werte aus der Branche Gesundheitswesen
Wertpapier | Kurs | Perf. % |
---|---|---|
0,6150 | +55,30 | |
0,6580 | +32,66 | |
1,3000 | +27,45 | |
1,3000 | +17,12 | |
0,9350 | +16,15 |
Wertpapier | Kurs | Perf. % |
---|---|---|
9,6600 | -19,57 | |
4,2400 | -23,47 | |
19,600 | -25,69 | |
3,6600 | -26,80 | |
3,1300 | -28,54 |
Bericht ist zwar nicht ganz so positiv für OSUR , aber immerhin (wg. Bewertung - was würde der erst zu yahoo sagen)
OraSure Not That Sure
Monday March 29, 2:54 pm ET
By W.D. Crotty
Diagnostics company OraSure Technologies (Nasdaq: OSUR - News) recently won FDA approval for its rapid oral-fluid HIV antibody test. The breakthrough is significant, with an estimated 40 million people harboring the virus without knowing it.
ADVERTISEMENT
The oral test is fast and, unlike a blood test, which requires a trained technician (and has its own set of associated safety and cost issues), can be administered virtually anywhere with minimal cost, training, or safety issues. Speed and ease of use are a winning combination.
As Jeff Hwang noted in December, the OraSure rapid HIV test has been available since Nov. 2002 for finger-stick whole blood. That test was upstaged in December when Trinity Biotech (Nasdaq: TRIB - News) received FDA approval for a 10-minute, one-step test for HIV in human serum, plasma, and whole blood. The oral-fluid test is another step forward.
Still, investors need to weigh two factors. First, the test is only approved for detecting the more common HIV-1 antibodies. True, the less common HIV-2 is most prevalent in western Africa, but if you are going to test (or be tested), don`t you want to test for both? Second, the company still needs to license HIV-2 patents held by Bio-Rad (AMEX: BIO - News). Although it is likely these patents will be nonexclusively licensed, it`s an uncertainty that could spell problems.
First Call analyst estimates are available through 2008. Even with a mean five-year growth rate of 19%, earnings are expected to reach just $0.36 a share by year-end 2008. After today`s 10% gain, the company sells at 30 times projected 2008 earnings. Rapidly growing rival Biosite (Nasdaq: BSTE - News) sells for 20 times trailing earnings, and much larger Dade Behring (Nasdaq: DADE - News) sells for 38 times trailing earnings.
The company`s pipeline is interesting, however. Although the FDA has asked for more data on an oral test for cocaine, opiates, amphetamine/methamphetamine, PCP, and marijuana, the company will launch the product into the European "roadside testing market" in April. You can bet that police would rather test oral fluids than urine, not to mention get back the results in a flash.
Salivating to own OraSure? Given the earnings outlook, you might check what happened to Trinity Biotech after its quick news-induced jump to $6.72 on Dec. 30. It closed Friday at $3.70 a share. Good news is great, but strong revenue and earnings growth and growing free cash flow ultimately win out.
OraSure Not That Sure
Monday March 29, 2:54 pm ET
By W.D. Crotty
Diagnostics company OraSure Technologies (Nasdaq: OSUR - News) recently won FDA approval for its rapid oral-fluid HIV antibody test. The breakthrough is significant, with an estimated 40 million people harboring the virus without knowing it.
ADVERTISEMENT
The oral test is fast and, unlike a blood test, which requires a trained technician (and has its own set of associated safety and cost issues), can be administered virtually anywhere with minimal cost, training, or safety issues. Speed and ease of use are a winning combination.
As Jeff Hwang noted in December, the OraSure rapid HIV test has been available since Nov. 2002 for finger-stick whole blood. That test was upstaged in December when Trinity Biotech (Nasdaq: TRIB - News) received FDA approval for a 10-minute, one-step test for HIV in human serum, plasma, and whole blood. The oral-fluid test is another step forward.
Still, investors need to weigh two factors. First, the test is only approved for detecting the more common HIV-1 antibodies. True, the less common HIV-2 is most prevalent in western Africa, but if you are going to test (or be tested), don`t you want to test for both? Second, the company still needs to license HIV-2 patents held by Bio-Rad (AMEX: BIO - News). Although it is likely these patents will be nonexclusively licensed, it`s an uncertainty that could spell problems.
First Call analyst estimates are available through 2008. Even with a mean five-year growth rate of 19%, earnings are expected to reach just $0.36 a share by year-end 2008. After today`s 10% gain, the company sells at 30 times projected 2008 earnings. Rapidly growing rival Biosite (Nasdaq: BSTE - News) sells for 20 times trailing earnings, and much larger Dade Behring (Nasdaq: DADE - News) sells for 38 times trailing earnings.
The company`s pipeline is interesting, however. Although the FDA has asked for more data on an oral test for cocaine, opiates, amphetamine/methamphetamine, PCP, and marijuana, the company will launch the product into the European "roadside testing market" in April. You can bet that police would rather test oral fluids than urine, not to mention get back the results in a flash.
Salivating to own OraSure? Given the earnings outlook, you might check what happened to Trinity Biotech after its quick news-induced jump to $6.72 on Dec. 30. It closed Friday at $3.70 a share. Good news is great, but strong revenue and earnings growth and growing free cash flow ultimately win out.
Die Lösung ist QTFV!
www.qt5inc.com
Haben Test für HIV 1 + 2 in der Pipeline.
Derzeit FDA Stufe 3.
http://www.targetsystemdiagnostics.com/target_Products.htm
HIV 1 & 2 Response: 10 Minutes
Sensitivity: 100%
Specificity: 99.8%
Zum Vergleich: ORASURE Response 20 Minutes + Specificity: "nur" 99.0%
Kurs von QTFV wurde von MM derb herunter gezockt. Erwarte in nächster Zeit 10000% in diesem Wert.
QTFV auf jeden Fall auf die WATCHLIST nehmen!
www.qt5inc.com
Haben Test für HIV 1 + 2 in der Pipeline.
Derzeit FDA Stufe 3.
http://www.targetsystemdiagnostics.com/target_Products.htm
HIV 1 & 2 Response: 10 Minutes
Sensitivity: 100%
Specificity: 99.8%
Zum Vergleich: ORASURE Response 20 Minutes + Specificity: "nur" 99.0%
Kurs von QTFV wurde von MM derb herunter gezockt. Erwarte in nächster Zeit 10000% in diesem Wert.
QTFV auf jeden Fall auf die WATCHLIST nehmen!
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-4,53 | |
-0,91 | |
+0,14 | |
0,00 | |
+0,59 | |
+0,21 | |
+0,66 | |
+0,42 | |
+0,20 | |
-2,90 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
173 | ||
50 | ||
38 | ||
36 | ||
32 | ||
29 | ||
28 | ||
28 | ||
27 | ||
26 |
27.02.24 · globenewswire · Orasure Technologies |
13.02.24 · globenewswire · Orasure Technologies |
04.01.24 · globenewswire · Orasure Technologies |
13.11.23 · globenewswire · Orasure Technologies |
23.10.23 · globenewswire · Orasure Technologies |
20.07.23 · globenewswire · Orasure Technologies |
20.07.23 · globenewswire · Orasure Technologies |
13.06.23 · globenewswire · Orasure Technologies |
10.05.23 · globenewswire · Orasure Technologies |
03.05.23 · globenewswire · Orasure Technologies |